The purpose of this study was to test the continuing validity of the hypothesis that neuropeptide Y (NPY) produced in the brain controls food intake through an interaction with the NPY Y 5 receptor subtype.
Introduction
Within the hypothalamus, neuropeptide Y (NPY) is synthesized in nerve cell bodies of the arcuate nucleus (ARC). Nerve ®bers from the arcuate nucleus project to the paraventricular nucleus (PVN) where the release of NPY is believed to initiate food intake. 1 Two lines of evidence support this hypothesis. Firstly, there is an increase in the synthesis and release of NPY in the ARC-PVN projection in both genetically obese and energy de®cient animals. 2, 3 Hypothalamic NPY levels are also high immediately before the consumption of food. 3, 4 Secondly, blockade of the synthesis or action of endogenous NPY within the brain using antisense oligonucleotides, anti-NPY antibodies and NPY receptor antagonists all lead to decreased food intake. 5 ± 7 While available evidence supports the concept that NPY controls food intake, it remains controversial through which receptor subtype this occurs. In man and in rats NPY receptors exist as 5 different subtypes termed Y 1 ± Y 5 . 8 Correlation studies indicate that the stimulation of food intake induced by a range of NPY analogs is closely linked to their af®nity for the NPY Y 1 and particularly the NPY Y 5 receptor subtype. 9 Further evidence in favor of the NPY Y 1 receptor subtype is mixed since blockade of this receptor lowers food intake while antisense oligonucleotides directed against the NPY Y 1 receptor paradoxically increase food intake. 10 ± 12 The evidence supporting a role for the NPY Y 5 receptor appears more consistent since antisense oligonucleotides directed against the NPY Y 5 receptor and a selective NPY Y 5 antagonist, CGP 71683A reduce food intake in free-feeding and energy deprived lean rats. 13 ± 15 However, the validity of the antisense approach to investigate the role of NPY receptors in the control of food intake has been questioned. 16 Furthermore, in the study referred to above, CGP 71683A was given only by intraperitoneal injection and there is little evidence that the compound actually penetrated into the brain to antagonize the actions of endogenous NPY on food intake. 15 This is pertinent since evidence is emerging for the existence of NPY receptors in the periphery with NPY Y 5 receptor recognition features. 17 Peripheral effects of the molecule may partly or completely explain the effects of CGP 71683A observed in the above study. 15 The hypothesis that endogenous NPY produced in the brain and acting through the NPY Y 5 receptor controls food intake would be signi®-cantly enhanced if a selective NPY Y 5 antagonist were administered directly into the brain and equivalent changes in food intake observed.
Therefore, the purpose of the present study was to test the continuing validity of the hypothesis that endogenous neuropeptide Y (NPY) acting on the NPY Y 5 receptor subtype present in the brain contributes to food intake. This hypothesis was tested by the central administration of a high af®nity NPY Y 5 antagonist, CGP 71683A to obese Zucker faafa rats in which hyperphagia is linked to increased levels of NPY within the hypothalamus.
Methods

Animals
The feeding experiments in these studies were conducted with both male obese Zucker faafa rats and male Wistar rats weighing 325 ± 350 g (Iffa Credo, L'arbresle, France). The animals were housed individually in wire-bottomed cages in a room with a 12 ha12 h lightadark cycle (lights on 7:30 am) at 22 AE 3 C and 55% relative humidity. Six mm diameter food pellets of the following composition (67.5% food¯our, 26.5% saccharose, 5% gum tragacanth, 1.25% magnesium stearate; A03 UAR, Orge, France) were available ad libitum. The pellets were available to the animals from a food hopper attached to the side of the cage. All animal procedures described in this study complied with French laws regulating animal experimentation (Decree No 87-848 19 October 1987 and the Ministerial Decree of 10 April 1988) and were also approved by the ethics committee of the Servier Research Institute.
Implantation of intraventricular cannulae
Rats were anesthetized with sodium pentobarbital (60 mgakg i.p.; Sano®, Libourne, France) and a stainless steel guide cannulae (Plastic Products Co, Roanoke, VA, USA) stereotaxically implanted into the right lateral ventricle at the following coordinates relative to the bregma: AP 70.8 mm, L 71.2 mm and V 73.5 mm. After a 7 day recovery period, during which the animals were handled every day to minimize non-speci®c stress, they were lightly anesthetized with Fore Áne (Abbott Laboratories, Queenborough, UK). Humanarat NPY (3.4 nmolakg in a volume of 2.5 ml, Neosystem S.A., Strasbourg, France) was then injected through the intraventricular cannulae. Immediately after injection, the animals quickly recovered and were returned to their home cages. Those animals responding within 2 h with a robust increase in food intake, indicating correct cannulae placement, were randomly assigned to different groups and studied in one of the following protocols.
Inhibition of NPY Ð induced food intake by CGP 71683A Starting at 9:00 am, Wistar rats or obese Zucker faafa rats were injected intracerebroventricularly (i.cv.) either with vehicle (2.5 ml) or with CGP 71683A (1.5 ± 100 nmolakg in 2.5 ml) 20 min prior to the injection of humanarat NPY (3.4 nmolakg in 2.5 ml). Measurements of food intake were made 2 h after injection. For each animal, food spillage was quanti®ed during each time period and food intake was corrected for this loss. At the end of the experiments, the animals were euthanised and the position of the cannulae assessed by the injection of 100 ml Evans blue (2 mgakg) followed by visual examination of the brain slices. Only data obtained from animals with correctly positioned cannulae were included in the ®nal data analysis.
Inhibition of spontaneous food intake in Zucker faafa rats by CGP 71683A During these experiments, cumulative food intake was measured for the light and dark phases and body weight was measured starting at 7:30 am. For each animal, food spillage was quanti®ed at the end of the light and dark periods and ®nal food intake was corrected for this loss. After a 3 day runin period, either vehicle (2.5 ml) or CGP 71683A was injected via the ventricular cannulae 1 ± 2 h before the dark phase on each of 7 consecutive days. Because of the large number of animals involved, the following experiments were conducted in 2 series. In series 1, the animals were injected i.cv. either with vehicle or CGP 71683A (1.5, 3.0 and 15 nmolakg in 2.5 ml). Food intake and body weight were measured for a further 2 days after stopping the injection of drugs. In series 2, the animals were injected i.cv. either with vehicle or CGP 71683A (30, 100 and 300 nmolakg in 2.5 ml). Food intake and body weight were measured for 10 days after the last injection of CGP 71683A. Cannulae placement was assessed in the animals of series 1 but not those in series 2 since brain pathology was immediately assessed at the end of the experiment as follows.
Brain pathology after central injection of CGP 71683A
In these experiments, the animals in series 2 above were anesthetized with iso¯urane. After exsanguination, the brain Binding of CGP 71683A to brain receptors and channels (Table 1) These experiments were performed to assess the af®nity of CGP 71683A for a variety of brain receptors and channels. CGP 71683A was initially studied at 2 different concentrations (10 mM and 100 nM). Ligand displacement by CGP 71683A of more than 30% at 100 nM, indicating a signi®cant interaction with the receptorachannel under study, prompted the construction of full displacement curves. Ki values were calculated so that direct comparisons could be made between the af®nity of CGP 71683A for each receptor.
Effect of CGP71683A on serotonin uptake into rat brain synaptosomes These experiments were performed according to previously described methods. 42 In brief, rat brain synaptosomes were incubated with tritiated imipramine and different concentrations of either CGP 71683A or unlabelled imipramine. The displacement curves obtained enabled the calculation of an EC 50 for each product.
Organ bath experiments
Male Sprague-Dawley rats and male New-Zealand rabbits (200 ± 220 g and 6 ± 7 weeks old respectively; Charles River, France) were euthanasized with an overdose of pentobarbital (Sano®, 250 mgakg i.p. and 40 mgakg i.v.). The ileum (an NPY-Y 4 enriched preparation), saphenous vein (an NPY-Y 1 enriched preparation), and aorta (a norepinephrine and serotonin assay) were removed from the rabbits. The epididymal portion of the vas deferens of the rat was removed (an NPY-Y 2 enriched preparation). All preparations were immersed in modi®ed Krebs ± Ringer salt solution of the following composition (in mM:NaCl 118.3; KCl 4.7; CaCl 2 The ability of CGP 71683A (10 mM and 100 nM) to displace the speci®c binding of a ®xed dose of an appropriate ligand to a variety of brain receptors and channels was assessed in these studies. Details of each assay can be found in the appropriate reference.
CGP 71683A and food intake O Della Zuana et al 2.5; MgSO 4 1.2; KH 2 PO 4 1.2; NaHCO 3 25; calcium-disodium EDTA 0.026; and glucose 11.1) at 4 C and cleaned of adherent connective tissue. The preparations were cut into segments and bathed in modi®ed Krebs ± Ringer solution (37 C) which was bubbled with 95% O 2 a5% CO 2 at pH 7.4 for isometric tension recording in the presence of agonists and antagonists as previously described. 43, 44 In brief, rabbit saphenous vein was contracted with NPY (0.1 nM ± 1 mM) and aorta with either norepinephrine or serotonin (0.1 nM ± 1 mM). The spontaneous contractions of the isolated rabbit ileum and the contractions of the electrically stimulated rat vas deferens were inhibited by hPP (0.1 ± 500 nM) and PYY (0.1 nM ± 1 mM) respectively. The response to each ligand was studied in the presence or absence of CGP 71683A (0.1 ± 10 mM).
Mean arterial blood pressure in the pithed rat Male normotensive rats (Sprague-Dawley, 325 ± 350 g, Charles River) were anaesthetized with sodium pentobarbital (60 mgakg i.p.). The animals were pithed with a stainlesssteel rod pushed through the right orbit into the spinal canal and were arti®cially ventilated (10 mlakg body weight of room air, 80 cyclesamin). A tail vein and a carotid artery were cannulated for drug administration and blood pressure measurement, respectively. After a 15 min equilibration period, a single agonist which was either NPY (1 ± 10 nmolakg), norepinephrine (0.1 ± 10 nmolakg) or serotonin (0.1 ± 10 nmolakg) was administered intravenously in a cumulative manner in the presence or absence of CGP71683A (3 ± 300 nmolakg) and changes in mean arterial pressure recorded.
Materials
In the feeding studies, CGP 71683A was dissolved initially in 100% ethanol and then diluted with arti®cial cerebral spinal¯uid (aCSF) to a ®nal concentration of 66% ethanola34% aCSF. The highest concentration of CGP 71683A injected in these studies approached the solubility limits of the drug in this vehicle. CGP 71683A was dissolved in 1% ethanol for intravenous administration and in 0.2% DMSO for administration to isolated tissues.
Data and statistical analysis
Data are presented as mean AE s.e. Signi®cance of effects over time were determined by a two-way analysis of variance with repeated measures on factor day. Post hoc testing was by Dunnett's test which compared CGP 71683A-treated groups with their respective controls on each day. In addition, the evolution of body weight was assessed by complementary analysis of the slopes based on the contrast method followed by Holm's adjustment. P values`0.05 were considered to indicate statistical signi®cance.
Results
Af®nity of CGP 71683A for NPY receptors (Table 2) CGP 71683A bound to the hY 5 receptor with high af®nity. In contrast, CGP 71683A had markedly less af®nity for hY 1 , hY 2 receptors and the hY 4 receptor.
Af®nity of CGP 71683A for non-NPY receptors in rat brain (Table 2) In rat brain CGP 71683A displayed a similarly high af®nity for muscarinic receptors and the substrate recognition site for serotonin reuptake as for the NPY hY 5 receptor. The af®nity of CGP 71683A for a-adrenergic receptors was approximately 100 fold less than for the NPY hY 5 receptor subtype.
Activity of CGP71683A in functional preparations
In rat brain synaptosomes, both CGP 71683A and the potent serotonin uptake inhibitor imipramine were shown to have similar IC 50 s (91 nM and 74 nM respectively).
In rabbit ileum (NPY Y 4 ), saphenous vein (NPY Y 1 ) and vas deferens (NPY Y 2 ) CGP 71683A exhibited intrinsic effects at 10 mM. At 10 mM, CGP 71683A did not antagonise the effects of the ligand on these tissues but did produce a statistically signi®cant potentiation of NPY-induced contractions in the rabbit saphenous vein. In rabbit aorta (used as a norpinephrine and serotonin assay) CGP 71683A was without intrinsic activity but produced a concentration-dependent leftward shift of the concentration-response curves to norepinephrine (but not to serotonin). This potentiation was signi®cant for a concentration of 1 mM CGP 71683A (results not shown).
Mean arterial blood pressure in pithed rats CGP 71683A (1 ± 300 nmolakg i.v.) produced a transient decrease in mean arterial pressure (5 ± 15 mmHg). Thirty minutes after injection the mean arterial pressure returned to baseline or to values slightly above baseline (1 ± 9 mmHg). Bolus i.v. injections of NPY (1 ± 10 nmolakg) induced a dosedependent increase in mean arterial pressure which was not affected by CGP 71683A (3 ± 300 nmolakg). In contrast, CGP 71683A (3 ± 300 nmolakg) induced a signi®cant leftward shift of the increase in mean arterial blood pressure produced by norepinephrine (0.1 ± 10 nmolakg). However, the increase in Inhibition of NPY-stimulated food intake by CGP 71683A (Figures 1 and 2 ) Initial dose-ranging studies were performed in Wistar rats. In these studies, injection of 3.4 nmolakg NPY into the right lateral ventricle induced a robust increase in food intake during the 2 h test period (Figure 1) . Doses of CGP 71683A between 1.5 and 15 nmolakg inhibited NPY-induced food intake in a dose-dependent manner. Doses higher than 15 nmolakg did not result in a greater inhibition of NPYinduced food intake. Although not as marked as in Wistar rats, NPY also produced a signi®cant increase in food intake in obese Zucker faafa rats (Figure 2) . Notably, the increase in food intake produced by NPY was signi®cantly inhibited almost to control levels by 15 nmolakg CGP 71683A.
Food intake and body weight during central administration of low doses of CGP 71683A to Zucker faafa rats ( Figure 3 ) Food intake during the run-in period in both the light and dark phases was well matched between the 4 groups. During the light phase and particularly during the dark phase, injection of vehicle produced a small reduction in food intake during the treatment period. None of the doses of CGP 71683A produced a signi®cant reduction in food intake from control values. Body weight during the run-in phase was well matched between the 4 groups and increased continuously throughout the experimental period. None of the doses of CGP 71683A produced a signi®cant change in body weight from control values.
Food intake and body weight during central administration of high doses of CGP 71683A to Zucker faafa rats (Figure 4 ) Food intake during the pre-treatment period in both the light and dark phases was well matched between the 4 groups. During both the light and dark phases, injection of vehicle produced a small reduction in food intake during the treatment period which returned to pretreatment levels when the injections were stopped. During the dark phase, injection of CGP 7183A reduced food intake in a dosedependent manner. At the highest dose administered (300 nmolakg) food intake fell slowly reaching a statistically signi®cant minimum on the treatment day 4 ± 5. Thereafter, despite continuing treatment food intake started to increase back towards control levels. During the post-treatment period, food intake was increased above control levels in those animals treated with the highest doses of CGP 71683A. In contrast to the marked effect during the dark phase, CGP 71683A did not signi®cantly affect food intake from control values during the light phase. In general, the animals appeared healthy both during and after the chronic injection of all doses of CGP 71683A. The animals injected with the higher doses of CGP 71683A became noticeably thinner than the control animals. Exceptionally, one animal died 1 day after the chronic injection of Figure 1 Inhibition of NPY-stimulated food intake in Wistar rats by CGP 71683A. In these experiments rats were treated either with vehicle, NPY (3.4 nmolakg) or NPY (3.4 nmolakg) CGP 71683A (1.5 ± 100 nmolakg) and changes in food intake monitored over the following 2 h period. Results expressed as mean AE s.e. from 17 animals per group. Statistics by analysis of variance followed by Dunnett's test.
+
Signi®cantly different from control values (0) at P`0.05. *Signi®cantly different from the NPYinjected group at P`0.05. In a separate series of experiments, injecting CGP 71683A alone at 100 nmolakg did not signi®cantly alter baseline food intake during the 2 h test period (controls: 0.97 AE 0.27 g; treated: 1.51 AE 0.29 g, P NS). Brain and liver pathology after central injection of CGP 71683A (Table 3, Figure 5 ) The animals described in Figure 4 were sacri®ced at the end of the study and the histology of the brain, and liver studied. Injection of vehicle was associated with a mild in¯ammation at the edge of the right lateral ventricle (the site of injection, Figure 5 ). However, this type of lesion was both more severe and more frequent in the rats receiving the highest doses of CGP 71683A in this study (100 and 300 nmolakg). Although fatty liver was present as expected in the control obese rats it was the general impression that this pathology appeared to cluster more in the animals receiving the 2 highest doses of CGP 71683A.
Discussion
The purpose of these experiments was to test the continuing validity of the hypothesis that neuropeptide Y (NPY) acting on the NPY Y 5 receptor subtype present in the brain controls food intake. This hypothesis was tested by the central administration of CGP 71683A to obese Zucker faafa rats. Presently, there are few tools available for investigating the role of the NPY Y 5 receptor in the control of food intake. CGP 71683A has recently been synthesized and shown to have a very high af®nity for the rat NPY Y 5 receptor subtype (IC 50 1.4 nM) but much less af®nity for NPY Y 1 , Y 2 and Y 4 receptors. 15 The results presented in this study con®rm Figure 3 Food intake and body weight during chronic central administration of CGP 71683A to Zucker faafa rats. After a 3 day run-in period to establish baseline values for food intake and body weight, CGP 71683A was injected i.cv. shortly before the onset of the dark phase on each of 7 consecutive days. Thereafter, the injections were stopped and food intake and body weight measured for a further 1 day. Open symbols represent the measurements during the light phase and closed symbols represent the measurements during the night phase. Morning body weights are presented in this ®gure. Results expressed as mean AE s.e. from 6 animals per group. Statistics by 2-way analysis of variance (treatment Â day) for repeated measures on factor day. CGP 71683A did not produce a signi®cant change in either food intake or body weight during the treatment period. Figure 4 Food intake and body weight during chronic central administration of CGP 71683A to Zucker faafa rats. After a 3 day run-in period to establish baseline values for food intake and body weight, CGP 71683A was injected i.cv. shortly before the onset of the dark phase on each of 7 consecutive days. Thereafter, the injections were stopped and food intake and body weight measured for a further 10 days. Open symbols represent the measurements during the light phase and closed symbols represent the measurements during the night phase. Morning body weights are presented in this ®gure. Results expressed as mean AE s.e. from 6 animals per group except at the highest dose of CGP 71683A where the results of 5 rats are presented. Statistics by 2-way analysis of variance (treatment Â day) for repeated measures on factor day followed by Dunnett's test for food intake and complementary analysis of the slopes based on the contrast method followed by Holm's adjustment. CGP 71683A at the highest dose produced a signi®cant reduction in food intake on treatment days 4, 5 and 6. *Signi®cantly different from control values at each time point P`0.05. A signi®cant difference in the slopes for food intake existed on days 9 ± 17 after treatment with CGP 71683A.
CGP 71683A and food intake O Della Zuana et al previously published data, that in addition have also demonstrated CGP 71683A to be an antagonist of the NPY Y 5 receptor. 15 Recently, CGP 71683A and a close analog have been used to show that NPY acting through the NPY Y 5 receptor plays an important role in the control of food intake and pituitary hormone release. 15, 45 On the basis of these studies and in view of its af®nity and selectivity, CGP 71683A is currently the reference compound for investigating the role of the NPY Y 5 receptor in the control of food intake. Since the characterization of other active and selective NPY At the end of the experiment illustrated in Figure 4 the brain and liver of each rat was removed and processed for histology. After embedding, sectioning and staining the brain and liver was sectioned and examined by a pathologist. For each animal the type and location of the observed lesions are described. *Numbers represent the internal code of every rat studied in each dose group for n 6 per group., , , indicate increasing lesion severity. Figure 5 Brain histology after the central injection of CGP 71683A. At the end of the experiments described in Figure 4 the rats were euthanized and the brains removed. After ®xing and embedding, sections were made through the brain. A representative section through the right lateral ventricle (the site of injection) following administration of 300 nmolakg CGP 71683A for 7 days is shown (left control, rat number 3 in Table 3 , right CGP 71683A, rat number 2 from Table 3 ). VL right lateral ventricle, 3V third ventricle, CT cannuale tract, N normal tissue, L lesioned tissue.
CGP 71683A and food intake O Della Zuana et al Y 5 antagonists had not been published at the time of conducting these studies, CGP 71683A was used to further de®ne the role of the NPY Y 5 receptors in the control of food intake. Despite having a very high af®nity for the NPY Y 5 receptor, initial dose-ranging studies in Wistar rats demonstrated that CGP 71683A only partially blocked the increase in food intake produced by exogenous NPY. There could be several reasons for this ®nding. Firstly, solubility limitations may hinder the access of CGP 71683A into the hypothalamus in concentrations high enough to completely block the actions of exogenous NPY. This may also explain why it was necessary to chronically administer CGP 71683A over several days to observe a fall in spontaneous food intake. Secondly, NPY receptors other than the Y 5 subtype may also be important in mediating NPY-induced feeding and so it is not possible to completely block NPY-induced food intake with a selective antagonist. This conclusion is supported by several recent studies suggesting the involvement of NPY receptors other than the Y 5 subtype in the control of food intake. 46, 47 Finally, CGP 71683A may have effects on other neural systems that could, in turn, modulate the changes in food intake produced by blockade of NPY Y 5 receptors. Although CGP 71683A is clearly a selective high af®nity antagonist of the NPY Y 5 receptor, details of the interaction of this molecule with receptors other than a-adrenergic have not been reported in detail. 15 Consequently, the mechanism by which CGP 71683A (and analogs) act to lower food intake both in present and previous studies remains an open question. 15, 45 In view of the large number of neurotransmitters and neuropeptides that can affect appetite, a thorough assessment of the overall selectivity of the molecule is essential for understanding how the compound ultimately acts to in¯u-ence food intake. The results in the present study show that CGP 71683A had a low af®nity for many receptors and channels except for adrenergic a 2 receptors, the serotonin reuptake recognition site and cholinergic muscarinic receptors. The af®nity of CGP 71683A for the serotonin reuptake site and muscarinic receptors was virtually identical to the af®nity of the compound for the NPY Y 5 receptor. Functional studies in isolated organs and in pithed rats con®rmed the lack of antagonistic properties of CGP 71683A toward NPY Y 1 , Y 2 and Y 4 receptor subtypes. However, in both studies intrinsic effects of CGP 71683A were observed. Although the origin of these effects was not identi®ed, these studies also con®rm the lack of selectivity of CGP 71683A against non-NPY receptors.
Both neurons containing NPY and neurons containing serotonin are in close anatomical proximity within the hypothalamus. 48 This close interaction has led to a number of studies suggesting that the local release of serotonin modulates the synthesis and release of NPY within the ARC-PVN pathway. For example, serotonin depletion of the brain leads to an increase in NPY levels in the PVN and to an increase in food intake. 49 In contrast, serotonin and serotonin agonists, most notably of the 5HT 2A subtype inhibit NPY-induced food intake, an effect which may be secondary to decreased NPY levels in the PVN. 50, 51 Taken to a logical conclusion the data suggest that serotonin tonically inhibits the synthesis and release of NPY and that the actions of serotonin on food intake may be mediated by this neuropeptide. Since CGP 71683A was de®ned as a 5-HT uptake inhibitor the associated decrease in food intake may partially be due to supression of the effects of NPY rather than to blockade of the NPY Y 5 receptor.
Areas of the brain controlling food intake contain a rich population of a 2 -adrenergic receptors. Stimulation of central a 2 -adrenergic receptors increases food intake while inhibition of a 2 -adrenergic receptors decrease food intake in either lean or genetically obese rodents. 52, 53 While showing appreciable af®nity for a 2 -receptors these studies do not de®ne CGP 71683A as an agonist or an antagonist. However, since CGP 71683A had to be given at much higher doses than needed to block the actions of exogenous NPY, a signi®cant interaction with the a 2 -receptor cannot be dismissed. Consequently, whether producing an increase or a decrease in food intake, the interpretation of the data obtained in this study would also be complicated by an interaction of CGP 71683A with the a 2 -receptor.
In contrast to adrenergic and serotonergic pathways, cholinergic pathways within the brain are not directly involved in the initiation of food intake but appear to be important in`shaping' feeding behavior, for example, by in¯uencing locomotor activity and cognitive processes such as motivation, reward, arousal and memory. Many of these actions of acetylcholine are mediated through muscarinic receptors in the limbic system. NPY Y 5 receptors and NPY containing neurons are present in the limbic system and receive inputs from ascending projections of the cholinergic system. 54 Thus a complex interrelationship exists between NPY and the cholinergic system in the control of food intake. 55, 56 Although CGP 71683A was not de®ned as an agonist or antagonist of muscarinic receptors in the present studies, the administration of a high af®nity muscarinic ligand could be expected to positively or negatively in¯uence food intake by modifying cognitive processes andaor locomotor activity. Cholinergic actions could therefore explain the effects of CGP 71683A observed in this study or may modulate positively or negatively the changes in food intake produced by blockade of NPY Y 5 receptors.
CGP 71683A has been shown to decrease food intake in various animal models after intraperitoneal administration. There is little evidence to suggest that these observations are due to an inherent toxicity of the compound. 15 In the present studies, inspection of the animals treated with all doses of CGP 71683A revealed them to be healthy and without any visible external signs of underlying pathology. Nonetheless, administration of CGP 71683A was associated with a dose-dependant in¯ammation and necrosis on the border of the right lateral ventricle (the site of injection). The cause of this pathology is not directly known and CGP 71683A and food intake O Della Zuana et al maybe related to an in¯ammatory activity inherent to the compound. Alternatively, precipitation of the compound within the brain may also give rise to a sterile in¯ammation of the ventricular wall. However, the presence of precipitated compound was not detected in the microscopic studies. Nonetheless, the in¯ammatory effect of CGP 71683A was most pronounced at the highest dose administered that also produced a signi®cant reduction in food intake. Chemokinesaintercrines produced in response to in¯ammation are potent inhibitors of feeding behavior. 57, 58 Thus the release of pro-in¯ammatory cytokines from the ventricular wall represents a plausible explanation for the reduction in food intake observed in these studies. It remains to be determined whether the reduction in food intake observed after intraperitoneal administration of CGP 71683A is mediated by in¯ammatory cytokines rather than blockade of NPY Y 5 receptors.
Recently, peptides having high af®nity and selectivity for the NPY Y 5 receptor have been shown to strongly stimulate food intake in rats. 59, 60 These results are in line with previous correlation studies indicating that the stimulation of appetite induced by a range of NPY analogs is closely linked to their af®nity for the NPY Y 5 receptor. 9 However, although exogenous NPY acting through the NPY Y 5 receptor can in¯uence food intake it does not automatically follow that treatment of animals with a selective NPY Y 5 antagonist will result in an overall change in food intake. This is because NPY acting through NPY Y 1 or other NPY receptors may be suf®cient to maintain normal appetite in the presence of NPY Y 5 receptor blockade. In this regard, it has recently been shown that the stimulatory effect of NPY on food intake cannot be inhibited with a selective NPY Y 5 antagonist free of af®nity for other receptors while the NPY Y 5 knockout mouse exhibits essentially normal food intake. 61 Thus, proof that blockade of the actions of endogenous NPY acting at the NPY Y 5 receptor can in¯uence food intake awaits studies with`cleaner' NPY Y 5 antagonists than CGP 71683A.
Conclusion
CGP 71683A is a high af®nity antagonist of the NPY Y 5 receptor but interacts with cholinergic-muscarinic receptors and binds to the serotonin reuptake recognition site with essentially identical af®nity. CGP 71683A also produced a dose-related in¯ammatory effect within the brain that appeared initially to correlate with the reduction in food intake. These results demonstrate that CGP 71683A is an unsuitable tool in vivo for investigating the role of the NPY Y 5 receptor in physiological processes including food intake ± a conclusion shared by others. 62 Non-speci®c effects may explain why this compound affects food intake. In view of the available evidence the hypothesis that the NPY Y 5 receptor is involved in the control of food intake remains to be conclusively proven.
